Exclusive Summary

• Utilizes an advanced Powder-Liquid Double-Chamber Bag (DCB) packaging, a Ready-to-Use (RTU) formulation that prevents secondary contamination and dosage errors, making it highly competitive for hospital tenders.
• While Cefuroxime API is off-patent, the DCB formulation operates in an oligopolistic 'blue ocean' globally, effectively bypassing the severe price wars of basic vial generics.
• Scheduled for an EU GMP inspection in Q4 2026, showcasing top-tier international quality compliance and offering a perfect window for overseas partners to secure distribution rights and initiate dossier filings now.
• Cefuroxime is a WHO Essential Medicine and a guideline-recommended first/second-line treatment for surgical prophylaxis and respiratory/UTI infections, ensuring a massive and rigid annual global demand in the hundreds of millions.
• Backed by China's mature high-end IV manufacturing supply chain, it offers significant manufacturing cost advantages compared to Western double-chamber bag products, ensuring lucrative margins for overseas distributors.